Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real‐world clinical setting. Methods We conducted a retrospective study including consecutive patients from nine public hospitals in south‐eastern Spain who received ocrelizumab after it was approved. Results A total of 228 MS patients were included (144 with relapsing–remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow‐up period was 12 months (range, 1‐32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow‐up period, 19 months). The most common adverse events reported were infusion‐related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID‐19. Interpretation The preliminary results in our real‐world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.

No abstract

Objective. Microstimulation via electrodes that penetrate the visual cortex creates visual perceptions called phosphenes. Besides providing electrical stimulation to induce perceptions, each electrode can be used to record the brain signals from the cortex region under the electrode which contains brain state information. Since the future visual prosthesis interfaces will be implanted chronically in the visual cortex of blind people, it is important to study the long-term stability of the signals acquired from the electrodes. Here, we studied the changes over time and the repercussions of electrical stimulation on the brain signals acquired with an intracortical 96-channel microelectrode array implanted in the visual cortex of a blind volunteer for 6 months. Approach. We used variance, power spectral density, correlation, coherence, and phase coherence to study the brain signals acquired in resting condition before and after the administration of electrical stimulation during a period of 6 months. Main Results. Variance and power spectral density up to 750 Hz do not show any significant trend in the 6 months, but correlation coherence and phase coherence significantly decrease over the implantation time and increase after electrical stimulation. Significance. The stability of variance and power spectral density in time is important for long-term clinical applications based on the intracortical signals collected by the electrodes. The decreasing trends of correlation, coherence, and phase coherence might be related to plasticity changes in the visual cortex due to electrical microstimulation.

No abstract